The FDA approval is based on late-stage data, which shows that GSK's Blujepa is at least as effective as a leading standard treatment for uncomplicated UTIs.

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...

GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

A 12-month interim analysis of the AGILE Phase III open-label extension study confirms that twice-yearly depemokimab, an ultra-long-acting anti-IL-5 biologic, maintains a favorable safety and efficacy ...

Overall, 72% of patients were exacerbation free and 96% did not require hospitalization or emergency department visits. GSK has submitted depemokimab for FDA approval.

Daniel J. Jackson In the previous phase 3 SWIFT-1/2 studies, two doses of depemokimab (GSK) administered at week 0 and 26 in addition to standard of care reduced asthma exacerbations by ...

GSK. “Our SWIFT and ANCHOR trials support depemokimab’s potential to suppress interleukin-5, a known driver of type 2 inflammation, to offer patients sustained inhibition of a key driver of ...

GSK. “Our SWIFT and ANCHOR trials support depemokimab’s potential to suppress interleukin-5, a known driver of type 2 inflammation, to offer patients sustained inhibition of a key driver of their ...

GSK Pushes First-in-Class Antibiotic for Uncomplicated UTI By March 26, the FDA is scheduled to release its verdict on GSK’s investigational antibiotic gepotidacin for the treatment of uncomplicated ...

GSK plc GSK announced that the FDA accepted its biologics license application (BLA) for pipeline candidate, depemokimab, in two indications. The BLA is seeking approval of the candidate as an add ...